Chapter 10 Computational Prediction of ADMET Properties: Recent Developments and Future Challenges

Annual Reports in Computational Chemistry

Volumn 1, Issue C, 2005, Pages 133-151

  Clark, David E ^a  

^a Argenta Discovery Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956724070     PISSN: 15741400     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1574-1400(05)01010-8     Document Type: Review

References (101)

1. Yu H., and Adedoyin A. ADME-Tox in drug discovery: integration of experimental and computational technologies. Drug Discov. Today 8 (2003) 852-861
2. Beresford A.P., Selick H.E., and Tarbit M.H. The emerging importance of predictive ADME simulation in drug discovery. Drug Discov. Today 7 (2002) 109-116
3. Van de Waterbeemd H., and Gifford E. ADMET in silico modelling: towards prediction paradise. Nat. Rev. Drug Discov. 2 (2003) 192-204
4. Lombardo F., Gifford E., and Shalaeva M.Y. In silico ADME prediction: data, models, facts and myths. Mini-rev. Med. Chem. 3 (2003) 861-875
5. Winiwarter S., Bonham N.M., Ax F., Hallberg A., Lennernaes H., and Karlen A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41 (1998) 4939-4949
6. Winiwarter S., Ax F., Lennernaes H., Hallberg A., Pettersson C., and Karlen A. Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. J. Mol. Graph. Model. 21 (2003) 273-287
7. Lennernaes H. Human intestinal permeability. J. Pharm. Sci. 87 (1998) 403-410
8. Ghose A.K., and Crippen G.M. Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships. I. Partition coefficients as a measure of hydrophobicity. J. Comput. Chem. 7 (1986) 565-577
9. Artursson P., and Tavelin S. Caco-2 and emerging alternatives for prediction of intestinal drug transport: a general overview. In: Artursson P., Lennernäs H., and van de Waterbeemd H. (Eds). Drug Bioavailability: Estimation of Solubility, Permeability and Bioavailability. Methods and Principles in Medicinal Chemistry Vol. 18 (2003), Wiley-VCH, Weinheim 72-89
10. Clark D.E. Computational prediction of intestinal absorption. In: Schleyer P.v.R., Jorgensen W.L., Schaefer III H.F., Schreiner P.R., Thiel W., and Glen R. (Eds). Encyclopedia of Computational Chemistry (2004), Wiley. http://www.mrw.interscience.wiley.com/ecc/articles/cu0049/frame.html
11. Stenberg P., Norinder U., Luthman K., and Artursson P. Experimental and computational screening models for the prediction of intestinal drug absorption. J. Med. Chem. 44 (2001) 1927-1937
12. Bergstroem C.A.S., Strafford M., Lazorova L., Avdeef A., Luthman K., and Artursson P. Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 46 (2003) 558-570
13. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44 (2000) 235-249
14. Lipinski C.A. Aqueous solubility in discovery, chemistry, and assay changes. In: Artursson P., Lennernäs H., and van de Waterbeemd H. (Eds). Drug Bioavailability: Estimation of Solubility, Permeability and Bioavailability. Methods and Principles in Medicinal Chemistry Vol. 18 (2003), Wiley-VCH, Weinheim 215-231
15. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
16. a and A log P98 values. Mol. Divers. 7 (2003) 69-87
17. Jorgensen W.L., and Duffy E.M. Prediction of drug solubility from structure. Adv. Drug Deliv. Rev. 54 (2002) 355-366
18. Huuskonen J. Estimation of aqueous solubility in drug design. Comb. Chem. High Throughput Screen. 4 (2001) 311-316
19. Clark D.E., and Grootenhuis P.D.J. Progress in computational methods for the prediction of ADMET properties. Curr. Opin. Drug Discov. Dev. 5 (2002) 382-390
20. Eroes D., Keri G., Koevesdi I., Szantai-Kis C., Meszaros G., and Oerfi L. Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods. Mini-Rev. Med. Chem. 4 (2004) 167-177
21. Cheng A., and Merz Jr. K.M. Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships. J. Med. Chem. 46 (2003) 3572-3580
22. 2, Accelrys Inc., 9685 Scranton Road, San Diego, CA 92121-3752, USA.
23. Yan A., and Gasteiger J. Prediction of aqueous solubility of organic compounds based on a 3D structure representation. J. Chem. Inf. Comput. Sci. 43 (2003) 429-434
24. Yan A., and Gasteiger J. Prediction of aqueous solubility of organic compounds by topological descriptors. QSAR Comb. Sci. 22 (2003) 821-829
25. Hemmer M.C., Steinhauer V., and Gasteiger J. Deriving the 3D structure of organic molecules from their infrared spectra. Vib. Spectrosc. 19 (1999) 151-164
26. Klopman G., and Zhu H. Estimation of the aqueous solubility of organic molecules by the group contribution approach. J. Chem. Inf. Comput. Sci. 41 (2001) 439-445
27. Hou T.J., Xia K., Zhang W., and Xu X.J. ADME evaluation in drug discovery. 4. Prediction of aqueous solubility based on atom contribution approach. J. Chem. Inf. Comput. Sci. 44 (2004) 266-275
28. Lind P., and Maltseva T. Support vector machines for the estimation of aqueous solubility. J. Chem. Inf. Comput. Sci. 43 (2003) 1855-1859
29. Zhao Y.H., Le J., Abraham M.H., Hersey A., Eddershaw P.J., Luscombe C.N., Butina D., Beck G., Sherborne B., Cooper I., and Platts J.A. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J. Pharm. Sci. 90 (2001) 749-784
30. Burton P.S., Goodwin J.T., Vidmar T.J., and Amore B.M. Predicting drug absorption: how nature made it a difficult problem. J. Pharmacol. Exp. Ther. 303 (2002) 889-895
31. Deretey E., Feher M., and Schmidt J.M. Rapid prediction of human intestinal absorption. Quant. Struct.-Act. Relat. 21 (2002) 493-506
32. Molecular Operating Environment (MOE), Chemical Computing Group, Inc., 1010 Sherbrooke St. West, Suite 910, Montreal, Quebec H3A 2R7, Canada.
33. Wildman S.A., and Crippen G.M. Prediction of physicochemical parameters by atomic contributions. J. Chem. Inf. Comput. Sci. 39 (1999) 868-873
34. Sun H. A universal molecular descriptor system for prediction of log P, log S, log BB and absorption. J. Chem. Inf. Comput. Sci. 44 (2004) 748-757 in press
35. Algorithm Builder, Pharma Algorithms, Inc., 591 Indian Road, Toronto, Ontario M6P 2C4, Canada.
36. Zmuidinavicius D., Didziapetris R., Japertas P., Avdeef A., and Petrauskas A. Classification structure-activity relations (C-SAR) in prediction of human intestinal absorption. J. Pharm. Sci. 92 (2003) 621-633
37. Oprea T.I. Property distribution of drug-related chemical databases. J. Comput.-Aided Mol. Des. 14 (2000) 251-264
38. Klopman G., Stefan L.R., and Saiakhov R.D. ADME evaluation 2. A computer model for the prediction of intestinal absorption in humans. Eur. J. Pharm. Sci. 17 (2002) 253-263
39. Klopman G. Artificial intelligence approach to structure-activity studies. Computer automated structure evaluation of biological activity of organic molecules. J. Am. Chem. Soc. 106 (1984) 7315-7321
40. van de Waterbeemd H., and Jones B.C. Predicting oral absorption and bioavailability. Prog. Med. Chem. 41 (2003) 1-59
41. Andrews C.W., Bennett L., and Yu L.X. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm. Res. 17 (2000) 639-644
42. Yoshida F., and Topliss J.G. QSAR model for drug human oral bioavailability. J. Med. Chem. 43 (2000) 2575-2585 see p. 4723 for erratum
43. Pintore M., van de Waterbeemd H., Piclin N., and Chretien J.R. Prediction of oral bioavailability by adaptive fuzzy partitioning. Eur. J. Med. Chem. 38 (2003) 427-431
44. Turner J.V., Glass B.D., and Agatonovic-Kustrin S. Prediction of drug bioavailability based on molecular structure. Anal. Chim. Acta 485 (2003) 89-102
45. Turner J.V., Maddalena D.J., and Agatonovic-Kustrin S. Bioavailability prediction based on molecular structure for a diverse series of drugs. Pharm. Res. 21 (2004) 68-82
46. Bains W., Gilbert R., Sviridenko L., Gascon J.-M., Scoffin R., Birchall K., Harvey I., and Caldwell J. Evolutionary computational methods to predict oral bioavailability QSPRs. Curr. Opin. Drug Discov. Dev. 5 (2002) 44-51
47. Mandagere A.K., and Jones B. Prediction of bioavailability. In: Artursson P., Lennernäs H., and van de Waterbeemd H. (Eds). Drug Bioavailability: Estimation of Solubility, Permeability and Bioavailability. Methods and Principles in Medicinal Chemistry Vol. 18 (2003), Wiley-VCH, Weinheim 444-460
48. Herrera-Ruiz D., and Knipp G.T. Current perspectives on established and putative mammalian oligopeptide transporters. J. Pharm. Sci. 92 (2003) 691-714
49. Swaan P.W., and Tukker J.J. Molecular determinants of recognition for the intestinal peptide carrier. J. Pharm. Sci. 86 (1997) 596-602
50. Swaan P.W., Koops B.C., Moret E.E., and Tukker J.J. Mapping the binding site of the small intestinal peptide carrier (PepT1) using comparative molecular field analysis. Recept. Channels 6 (1998) 189-200
51. Bailey P.D., Boyd C.A.R., Bronk J.R., Collier I.D., Meredith D., Morgan K.M., and Temple C.S. How to make drugs orally active: a substrate template for peptide transporter PepT1. Angew. Chem. Int. Ed. 39 (2000) 506-508
52. Gebauer S., Knuetter I., Hartrodt B., Brandsch M., Neubert K., and Thondorf I. Three-dimensional quantitative structure-activity relationship analyses of peptide substrates of the mammalian H+/peptide cotransporter PEPT1. J. Med. Chem. 46 (2003) 5725-5734
53. Zhang E.Y., Phelps M.A., Cheng C., Ekins S., and Swaan P.W. Modeling of active transport systems. Adv. Drug Deliv. Rev. 54 (2002) 329-354
54. Lin J.H., and Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42 (2003) 59-98
55. Stouch T.R., and Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev. 54 (2002) 315-328
56. Seelig A., Landwojtowicz E., Fischer H., and Li Blatter X. Towards P-glycoprotein structure-activity relationships. In: Artursson P., Lennernäs H., and van de Waterbeemd H. (Eds). Drug Bioavailability: Estimation of Solubility, Permeability and Bioavailability. Methods and Principles in Medicinal Chemistry Vol. 18 (2003), Wiley-VCH, Weinheim 461-492
57. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov. Today 9 (2004) 276-285
58. Gombar V.K., Polli J.W., Humphreys J.E., Wring S.A., and Serabjit-Singh C.S. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J. Pharm. Sci. 93 (2004) 957-968
59. Norinder U., and Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Deliv. Rev. 54 (2002) 291-313
60. Clark D.E. In silico prediction of blood-brain barrier permeation. Drug Discov. Today 8 (2003) 927-933
61. Hou T.J., and Xu X.J. ADME evaluation in drug discovery. 3. Modeling blood-brain barrier partitioning using simple molecular descriptors. J. Chem. Inf. Comput. Sci. 43 (2003) 2137-2152
62. Hutter M.C. Prediction of blood-brain barrier permeation using quantum chemically derived information. J. Comput.-Aided Mol. Des. 17 (2003) 415-433
63. Subramanian G., and Kitchen D.B. Computational models to predict blood-brain barrier permeation and CNS activity. J. Comput.-Aided Mol. Des. 17 (2003) 643-664
64. Adenot M., and Lahana R. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates. J. Chem. Inf. Comput. Sci. 44 (2004) 239-248
65. Liu X., Tu M., Kelly R.S., Chen C., and Smith B.J. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab. Dispos. 32 (2004) 132-139
66. Advanced Chemistry Development, Inc., 90 Adelaide Street West, Suite 600, Toronto, Ontario M5H 3V9, Canada.
67. Colmenarejo G. In silico prediction of drug-binding strengths to human serum albumin. Med. Res. Rev. 3 (2003) 275-301
68. Hajduk P.J., Mendoza R., Petros A.M., Huth J.R., Bures M., Fesik S.W., and Martin Y.C. Ligand binding to domain-3 of human serum albumin: a chemometric analysis. J. Comput.-Aided Mol. Des. 17 (2003) 93-102
69. van de Waterbeemd H., Smith D.A., and Jones B.C. Lipophilicity in PK design: methyl, ethyl, futile. J. Comput.-Aided Mol. Des. 15 (2001) 273-286
70. Colmenarejo G., Alvarez-Pedraglio A., and Lavandera J.-L. Cheminformatic models to predict binding affinities to human serum albumin. J. Med. Chem. 44 (2001) 4370-4378
71. Hall L.M., Hall L.H., and Kier L.B. Modeling drug albumin binding affinity with E-state topological structure representation. J. Chem. Inf. Comput. Sci. 43 (2003) 2120-2128
72. Kerns E.H., and Li D. Pharmaceutical profiling in drug discovery. Drug Discov. Today 8 (2003) 316-323
73. Gombar V.K., Silver I.S., and Zhao Z. Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability. Curr. Top. Med. Chem. 3 (2003) 1205-1225
74. Shen M., Xiao Y., Golbraikh A., Gombar V.K., and Tropsha A. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. J. Med. Chem. 46 (2003) 3013-3020
75. Ekins S. In silico approaches to predicting drug metabolism, toxicology and beyond. Biochem. Soc. Trans. 31 (2003) 611-614
76. Bursi R., Grootenhuis A., van der Louw J., Verhagen J., de Gooyer M., Jacobs P., and Leysen D. Structure-activity relationship study of human liver microsomes-catalyzed hydrolysis rate of ester prodrugs of MENT by comparative molecular field analysis (CoMFA). Steroids 68 (2003) 213-220
77. Lewin J.L., and Cramer C.J. Rapid quantum mechanical models for the computational estimation of C-H bond dissociation energies as a measure of metabolic stability. Mol. Pharm. 1 (2004) 128-135
78. Vermeulen N.P.E. Prediction of drug metabolism: the case of cytochrome P450 2D6. Curr. Top. Med. Chem. 3 (2003) 1227-1239
79. Afzelius L., Zamora I., Masimirembwa C.M., Karlen A., Andersson T.B., Mecucci S., Baroni M., and Cruciani G. Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. J. Med. Chem. 47 (2004) 907-914
80. Kirton S.B., Baxter C.A., and Sutcliffe M.J. Comparative modeling of cytochromes P450. Adv. Drug Deliv. Rev. 54 (2002) 385-406
81. Lewis D.F.V. P450 structures and oxidative metabolism of xenobiotics. Pharmacogenomics 4 (2003) 387-395
82. Williams P.A., Cosme J., Ward A., Angove H.C., Vinkovic D.M., and Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424 (2003) 464-468
83. Astex determines structure of the key drug metabolising enzyme - human cytochrome P450 3A4, press release, October 28, 2002, http://www.astex-technology.com/press_release.jsp?press_release_id=58.
84. Lewis D.F.V., Dickins M., Lake B.G., and Goldfarb P.S. A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions. Drug Metab. Drug Interact. 19 (2003) 189-210
85. Lewis D.F.V., Dickins M., Lake B.G., and Goldfarb P.S. Investigation of enzyme selectivity in the human CYP2C subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic template. Drug Metab. Drug Interact. 19 (2003) 257-285
86. Lewis D.F.V., Lake B.G., Dickins M., and Goldfarb P.S. Homology modelling of CYP2A6 based on the CYP2C5 crystallographic template: enzyme-substrate interactions and QSARs for binding affinity and inhibition. Toxicol. In Vitro 17 (2003) 179-190
87. Lewis D.F.V., Lake B.G., Dickins M., Ueng Y.-F., and Goldfarb P.S. Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure. Xenobiotica 33 (2003) 239-254
88. Lewis D.F.V., Lake B.G., Bird M.G., Loizou G.D., Dickins M., and Goldfarb P.S. Homology modelling of human CYP2E1 based on the CYP2C5 crystal structure: investigation of enzyme-substrate and enzyme-inhibitor interactions. Toxicol. In Vitro 17 (2003) 93-105
89. de Groot M.J., and Ekins S. Pharmacophore modeling of cytochromes P450. Adv. Drug Deliv. Rev. 54 (2002) 367-383
90. Ekins S., Stresser D.M., and Williams J.A. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci. 24 (2003) 161-166
91. Lewis D.F.V. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr. Med. Chem. 10 (2003) 1955-1972
92. Lewis D.F.V. Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s. Inflammopharmacology 11 (2003) 43-73
93. Ekins S., Berbaum J., and Harrison R.K. Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab. Dispos. 31 (2003) 1077-1080
94. Susnow R.G., and Dixon S.L. Use of robust classification techniques for the prediction of human cytochrome P450 2D6 inhibition. J. Chem. Inf. Comput. Sci. 43 (2003) 1308-1315
95. Singh S.B., Shen L.Q., Walker M.J., and Sheridan R.P. A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules. J. Med. Chem. 46 (2003) 1330-1336
96. Mankowski D.C., and Ekins S. Prediction of human drug metabolizing enzyme induction. Curr. Drug Metab. 4 (2003) 381-391
97. Greene N. Computer systems for the prediction of toxicity: an update. Adv. Drug Deliv. Rev. 54 (2002) 417-431
98. Dearden J.C. In silico prediction of drug toxicity. J. Comput.-Aided Mol. Des. 17 (2003) 119-127
99. Feng J., Lurati L., Ouyang H., Robinson T., Wang Y., Yuan S., and Young S.S. Predictive toxicology: benchmarking molecular descriptors and statistical methods. J. Chem. Inf. Comput. Sci. 43 (2003) 1463-1470
100. Fernandez D., Ghanta A., Kauffman G.W., and Sanguinetti M.C. Physicochemical features of the hERG channel drug binding site. J. Biol. Chem. 279 (2004) 10120-10127
101. Nestorov I. Whole body pharmacokinetic models. Clin. Pharmacokinet. 42 (2003) 883-908